share_log

歌禮製藥-B：翌日披露報表

ASCLETIS-B: Next Day Disclosure Return

香港交易所 ·  Feb 15 06:57
Summary by Moomoo AI
歌禮製藥有限公司於2024年2月15日提交了翌日披露報表，披露了自2023年12月19日至2024年2月15日期間，公司進行了多次股份購回但未註銷的活動。根據報表，公司在上述期間內共購回了68,100,000股普通股，佔已發行股份的6.2642%。最後一次購回發生在2024年2月15日，當日購回500,000股，每股價格介於HKD 1.69至HKD 1.73之間，總付出金額為HKD 852,830。該系列股份購回活動是根據香港聯合交易所有限公司證券上市規則的相關條款進行的，並且已獲得公司董事會的正式授權批准。
歌禮製藥有限公司於2024年2月15日提交了翌日披露報表，披露了自2023年12月19日至2024年2月15日期間，公司進行了多次股份購回但未註銷的活動。根據報表，公司在上述期間內共購回了68,100,000股普通股，佔已發行股份的6.2642%。最後一次購回發生在2024年2月15日，當日購回500,000股，每股價格介於HKD 1.69至HKD 1.73之間，總付出金額為HKD 852,830。該系列股份購回活動是根據香港聯合交易所有限公司證券上市規則的相關條款進行的，並且已獲得公司董事會的正式授權批准。
Song Pharmaceutical Co., Ltd. filed a Next Day Disclosure Report on February 15, 2024, disclosing that the Company conducted multiple share repurchases but not delisted activities between December 19, 2023 and February 15, 2024. According to the report, the company repurchased a total of 68,100,000 shares of ordinary shares during the above period, representing 6.2642% of the issued shares. The last repurchase took place on February 15, 2024. 500,000 shares were repurchased on that day, priced between HKD 1.69 and HKD 1.73 for a total payout of HKD 852,830. This series of share repurchases has been conducted under the relevant terms of the Listing Rules of the Stock Exchange of Hong Kong Stock Exchange Limited and has been formally authorised by the Board of Directors of the Company.
Song Pharmaceutical Co., Ltd. filed a Next Day Disclosure Report on February 15, 2024, disclosing that the Company conducted multiple share repurchases but not delisted activities between December 19, 2023 and February 15, 2024. According to the report, the company repurchased a total of 68,100,000 shares of ordinary shares during the above period, representing 6.2642% of the issued shares. The last repurchase took place on February 15, 2024. 500,000 shares were repurchased on that day, priced between HKD 1.69 and HKD 1.73 for a total payout of HKD 852,830. This series of share repurchases has been conducted under the relevant terms of the Listing Rules of the Stock Exchange of Hong Kong Stock Exchange Limited and has been formally authorised by the Board of Directors of the Company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more